Welcome to our dedicated page for QUEST DIAGNOSTICS SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics (DGX) filed a notice under Rule 144 for a planned sale of common stock. The notice covers the proposed sale of 1,250 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 239700.00.
The shares to be sold were acquired from the issuer through restricted stock vesting on several dates in 2024 and through dividend reinvestment. Individual acquisitions listed include 211, 431 and 455 common shares from restricted stock vesting in May 2024, and 77 and 76 common shares from dividend reinvestment in July and October 2024, respectively. The notice also reports that 111,242,362 common shares were outstanding.
Quest Diagnostics senior executive Mark E. Delaney, SVP & Chief Commercial Officer, reported stock option exercises and a share sale in Quest Diagnostics Inc. common stock. On 11/18/2025, he exercised 7,846 stock options at an exercise price of $144.47 per share and 100 stock options at $143.33 per share, acquiring the same number of Quest Diagnostics shares. On the same date, he sold 7,946 shares of common stock at a price of $187.35 per share. Following these transactions, he directly owned 7,530 shares of Quest Diagnostics common stock. The filing notes that the exercise and sale were carried out under a pre-arranged Rule 10b5-1 sales plan adopted by the reporting person.
Quest Diagnostics (DGX) reported a planned sale of common stock under Rule 144. The notice covers the potential sale of 7,946 common shares through Fidelity Brokerage Services on the NYSE, with an indicated aggregate market value of $1,488,683.10. These shares were acquired on 11/18/2025 by exercising stock options originally granted on 03/21/2022 (7,846 shares) and 02/23/2023 (100 shares), with payment made in cash. The filing notes that there were 111,242,362 common shares outstanding at the time referenced, giving investors context for the relative size of this planned sale.
Quest Diagnostics (DGX) CEO and President James E. Davis reported a disposition of common stock tied to equity compensation. On 11/05/2025, 7,143 shares were withheld and delivered to the issuer at $175.57 per share (Code F) to cover tax obligations arising from the vesting of restricted stock units. Following this tax withholding, Davis directly beneficially owned 120,480 shares.
Quest Diagnostics (DGX) disclosed an insider transaction by its Executive Vice President & CFO. On 10/21/2025, the officer acquired 68 shares of common stock at a price of $189.081 per share, reported as an acquisition through a dividend reinvestment plan. Following this transaction, the officer directly beneficially owns 25,741 shares. The filing also notes that dividend reinvestment plan shares are eligible for deferred reporting on Form 5 under Rule 16a-6, but the officer elected to report early on this Form 4.
Quest Diagnostics (DGX) reported an insider transaction by its SVP for Diagnostic Services. On 10/21/2025, the officer acquired 46 shares of common stock at $189.079, as noted in a footnote describing purchases via a dividend reinvestment plan eligible for deferred reporting under Rule 16a-6 but reported early. Following this, direct beneficial ownership stood at 15,333 shares.
Quest Diagnostics (DGX): A company officer reported an insider transaction on a Form 4. On 10/21/2025, the SVP, Clinical Solutions acquired 15 shares of common stock at $189.076 per share.
Following this transaction, the reporting person beneficially owns 8,379 shares directly, plus 358 shares indirectly through a trust and 1,635 shares indirectly via the Company’s 401(k) plan.
Per the footnotes, the 15 shares were acquired through a dividend reinvestment plan and are eligible for deferred reporting on Form 5 under Rule 16a-6; the reporting person chose to report them early.
Quest Diagnostics (DGX) director Gary M. Pfeiffer reported a sale of common stock. On 10/22/2025, he sold 1,482 shares at $182.40 per share, and reported 29,431 shares beneficially owned directly after the transaction.
The filing also records an intra-plan transfer on 10/23/2025 within the company’s Amended and Restated Deferred Compensation Plan for Directors. 4,413.284 phantom common stock units—payable in cash and representing an equivalent number of shares—were transferred from the company stock fund to another investment option at a listed price of $190.58.
Quest Diagnostics (DGX) reported an insider transaction by a director. On 10/21/2025, the director acquired 70 shares of common stock at $189.082 per share, as disclosed on a Form 4.
The filing states the shares were acquired through a dividend reinvestment plan administered by the broker and were eligible for deferred reporting on Form 5 under Rule 16a-6; the reporting person chose to report early here. Following the transaction, the director beneficially owns 18,287 shares, held directly.
Quest Diagnostics (DGX) reported an insider transaction on Form 4. SVP & Chief Commercial Officer Mark E. Delaney acquired 15 shares of common stock on 10/21/2025 at $189.077 per share via a dividend reinvestment plan. Following the transaction, he beneficially owns 7,530 shares, held directly. The filing notes the transaction is eligible for deferred reporting under Rule 16a-6 and was reported early.